Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 447-457

  Doesch, Andreas O ^a   Zhao, Li ^a   Gleissner, Christian A ^a   Akhavanpoor, Mohammadreza ^a   Rohde, David ^a   Okuyucu, Deniz ^a   Hakimi, Maani ^a   Dengler, Thomas J ^b   Katus, Hugo A ^a   Erbel, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Department of Cardiology   (Germany)

Author keywords

Atherosclerosis; B7; CD86; Costimulation

Indexed keywords

B7 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN INHIBITOR; RHUDEX; THROMBOPLASTIN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CHEMOKINE; CYTOKINE;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CAROTID ATHEROSCLEROSIS; CCL2 GENE; CONTROLLED STUDY; CYTOKINE RESPONSE; EX VIVO STUDY; HUMAN; HUMAN CELL; ICAM 1 GENE; IFN GAMMA GENE; IL 10 GENE; IL 6 GENE; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; INFLAMMATION; INTRACELLULAR SIGNALING; NEGATIVE FEEDBACK; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TF GENE; TNF ALPHA GENE; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BIOSYNTHESIS; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIGENS, CD80; ATHEROSCLEROSIS; CHEMOKINES; CYTOKINES; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MAP KINASE SIGNALING SYSTEM; T-LYMPHOCYTES;

EID: 84900417518     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S59594     Document Type: Article

References (49)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340(2):115-126.
2. Galkina E, Ley K. Immune and infammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165-197.
3. Virmani R, Kolodgie FD, Burke A P, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classifcation scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262-1275.
4. Erbel C, Sato K, Meyer FB, et al. Functional profle of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol. 2007;102(2):123-132.
5. Wick G, Knofach M, Xu Q. Autoimmune and infammatory mechanisms in atherosclerosis. Annu Rev Immunol. 2004;22:361-403.
6. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(2):116-126.
7. Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993;262(5135):909-911.
8. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 1994;180(2):631-640.
9. Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80. J Immunol. 1998;161(8):3919-3924.
10. Inobe M, Aoki N, Linsley PS, et al. The role of the B7-1a molecule, an alternatively spliced form of murine B7-1 (CD80), on T cell activation. J Immunol. 1996;157(2):582-588.
11. Chai JG, Vendetti S, Amofah E, Dyson J, Lechler R. CD152 ligation by CD80 on T cells is required for the induction of unresponsive-ness by costimulation-deficient antigen presentation. J Immunol. 2000;165(6):3037-3042.
12. Lanier LL, O'Fallon S, Somoza C, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol. 1995;154(1):97-105.
13. Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibi-tion in atherosclerosis. Circ Res. 2008;103(11):1220-1231.
14. Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman AH. B7-1/ B7-2 costimulation regulates plaque antigen-specifc T-cell responses and atherogenesis in low-density lipoprotein receptor-defcient mice. Circulation. 2004;109(16):2009-2015.
15. Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12(2):178-180.
16. de Boer OJ, Hirsch F, van der Wal AC, van der Loos CM, Das PK, Becker AE. Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specifc T lymphocyte activation. Atherosclerosis. 1997;133(2):227-234.
17. Haanstra KG, Endell J, Estévâo D, Kondova I, Jonker M. Blocking T cell co-stimulation using a CD80 blocking small molecule reduces delayed type hypersensitivity responses in rhesus monkeys. Clin Exp Immunol. 2009;158(1):91-98.
18. Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol. 2000;20(5):1177-1178.
19. Gleissner CA, Shaked I, Erbel C, Böckler D, Katus HA, Ley K. CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circ Res. 2010;106(1):203-211.
20. Erbel C, Chen L, Bea F, et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol. 2009;183(12):8167-8175.
21. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke. 2006;37(7): 1923-1932.
22. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM. Synergistic proinfammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation. 2007;116(18):2043-2052.
23. Lu YC, Ye h WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42(2):145-151.
24. Edfeldt K, Swedenborg J, Hansson GK, Ya n ZQ. Expression of tolllike receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105(10):1158-1161.
25. Monaco C. The tolls and dangers of atherosclerotic disease. Curr Pharm Biotechnol. 2012;13(1):77-87.
26. Lim W, Gee K, Mishra S, Kumar A. Regulation of B7.1 costimulatory molecule is mediated by the IFN regulatory factor-7 through the activation of JNK in lipopolysaccharide-stimulated human monocytic cells. J Immunol. 2005;175(9):5690-5700.
27. Curiel RE, Garcia CS, Rottschafer S, Bosco MC, Espinoza-Delgado I. Enhanced B7-2 gene expression by interferon-gamma in human mono-cytic cells is controlled through transcriptional and posttranscriptional mechanisms. Blood. 1999;94(5):1782-1789.
28. Creery WD, Diaz-Mitoma F, Filion L, Kumar A. Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which infuence the development of T helper cell phenotype. Eur J Immunol. 1996;26(6):1273-1277.
29. Mattern T, Flad HD, Brade L, Rietschel ET, Ulmer AJ. Stimulation of human T lymphocytes by LPS is MHC unrestricted, but strongly dependent on B7 interactions. J Immunol. 1998;160(7):3412-3418.
30. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134(1):33-46.
31. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170(2):191-203.
32. Zhang X, Niessner A, Nakajima T, et al. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ Res. 2006;98(4): 524-531.
33. Harvey EJ, Ramji D P. Interferon-gamma and atherosclerosis: pro- or anti-atherogenic? Cardiovasc Res. 2005;67(1):11-20.
34. Luyendyk J P, Piper JD, Tencati M, et al. A novel class of antioxidants inhibit LPS induction of tissue factor by selective inhibition of the activation of ASK1 and MAP kinases. Arterioscler Thromb Vasc Biol. 2007;27(8):1857-1863.
35. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 1996;127(2):263-271.
36. O'Garra A, Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007;7(6):425-428.
37. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205-218.
38. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-defcient mice. Mol Cell. 1998;2(2):275-281.
39. DeGraba TJ. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology. 1997; 49(5 Suppl 4):S15-S19.
40. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008;105(29):10113-10118.
41. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180(9):5771-5777.
42. Cao S, Zhang X, Edwards J P, Mosser DM. NF-kappaB1 (p50) homodi-mers differentially regulate pro- and anti-infammatory cytokines in macrophages. J Biol Chem. 2006;281(36):26041-26050.
43. Zhang X, Edwards J P, Mosser DM. Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription. J Immunol. 2006;177(2):1282-1288.
44. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity. 2009;31(4):539-550.
45. Triantaflou M, Triantaflou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol. 2002;23(6): 301-304.
46. Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect. 2002;4(9): 903-914.
47. Oberbach A, Schlichting N, Blüher M, et al. Palmitate induced IL-6 and MCP-1 expression in human bladder smooth muscle cells provides a link between diabetes and urinary tract infections. PLoS One. 2010;5(5):e10882.
48. Kogut MH, Genovese KJ, He H, Kaiser P. Flagellin and lipopoly-saccharide up-regulation of IL-6 and CXCLi2 gene expression in chicken heterophils is mediated by ERK1/2-dependent activation of AP-1 and NF-kappaB signaling pathways. Innate Immun. 2008;14(4): 213-222.
49. Nakahira M, Ahn HJ, Park WR, et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol. 2002;168(3):1146-1153.